Joan Lo to Bone Density Conservation Agents
This is a "connection" page, showing publications Joan Lo has written about Bone Density Conservation Agents.
Connection Strength
6.822
-
Changing trends in bisphosphonate therapy: a twenty-five-year surveillance in a single US integrated healthcare system. Osteoporos Int. 2025 Apr; 36(4):741-747.
Score: 0.912
-
Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord. 2020 Dec 03; 21(1):801.
Score: 0.682
-
Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019 Dec; 30(12):2515-2520.
Score: 0.628
-
Vitamin D Status Among Older Women Initiating Osteoporosis Therapy. J Am Geriatr Soc. 2019 10; 67(10):2207-2208.
Score: 0.624
-
Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. J Manag Care Spec Pharm. 2019 Jun; 25(6):719-723.
Score: 0.615
-
Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System. J Manag Care Spec Pharm. 2017 Apr; 23(4):503-512.
Score: 0.529
-
Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone. 2012 Sep; 51(3):524-7.
Score: 0.378
-
Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg. 2012 Aug; 70(8):1844-53.
Score: 0.377
-
Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010 Sep; 68(9):2232-40.
Score: 0.335
-
Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg. 2010 Mar; 68(3):508-14.
Score: 0.324
-
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010 Feb; 68(2):243-53.
Score: 0.314
-
Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg. 2009 Jul; 67(7):1363-72.
Score: 0.309
-
Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17(6):922-8.
Score: 0.247
-
The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure. J Foot Ankle Surg. 2020 Mar - Apr; 59(2):269-273.
Score: 0.162
-
Determinants of Oral Bisphosphonate Use Beyond 5 Years. J Manag Care Spec Pharm. 2020 Feb; 26(2):197-202.
Score: 0.161
-
Changing Patterns in Oral Bisphosphonate Initiation in Women between 2004 and 2012. J Am Geriatr Soc. 2017 03; 65(3):656-658.
Score: 0.131
-
Clinical correlates of atypical femoral fracture. Bone. 2012 Jul; 51(1):181-4.
Score: 0.093